title: Biological Responsiveness and Metabolic Performance of Liposome-Encapsulated Hemoglobin (Hemoglobin-Vesicles) in Apolipoprotein E-Deficient Mice after Massive Intravenous Injection.
abstract: The hemoglobin-vesicle (HbV), a vesicle in which a concentrated human hemoglobin solution is encapsulated, was developed as an artificial oxygen carrier. Although HbV has a favorable safety, metabolic, and excretion performance in healthy animals, the effect of a massive amount of HbV, which also contains a large amount of a lipid component including cholesterol, on physiological response and metabolic performance under hyperlipidemic conditions is unclear. The aim of this study was to evaluate whether administration of HbV causes toxicity in apolipoprotein E-deficient mice (hyperlipidemic model mice). Apolipoprotein E-deficient mice were given a single injection of HbV (2000 mg hemoglobin/kg), and physiological responses and metabolic profiles were monitored for 14 d thereafter. All the mice tolerated the massive amount of HbV and survived, and adequate biocompatibility was observed. Serum biochemical parameters indicate that liver and kidney function were not remarkably affected, and morphological changes in the liver and spleen were negligible. Lipid parameters in serum were significantly increased until 3 d after HbV administration, but recovered within 7 d after the administration. In a pharmacokinetic study, HbV was mainly found distributed in the liver and spleen, and disappeared from the body within 14 d. In conclusion, even under conditions of hyperlipidemia, a massive dose of HbV and its components resulted in favorable biological compatibility, metabolic, and excretion profiles. These findings provide further support for the safety of HbV for clinical use.
authors.affiliation: Faculty of Pharmaceutical Sciences, Sojo University.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Taguchi
authors.forename: Saori
authors.initials: S
authors.lastname: Nagao
authors.forename: Keishi
authors.initials: K
authors.lastname: Yamasaki
authors.forename: Hiromi
authors.initials: H
authors.lastname: Sakai
authors.forename: Hakaru
authors.initials: H
authors.lastname: Seo
authors.forename: Toru
authors.initials: T
authors.lastname: Maruyama
authors.forename: Masaki
authors.initials: M
authors.lastname: Otagiri
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics; D006454:Hemoglobins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D006949:Hyperlipidemias / Q000378:metabolism*; D007275:Injections, Intravenous; D008081:Liposomes; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D013154:Spleen / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
chemical_list: D001057:Apolipoproteins E; D006454:Hemoglobins; D008081:Liposomes